Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work
Amgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the company “very encouraged,” and it planned …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
